BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy participants and participants with primary Sjögren's syndrome. The results will guide the future clinical development with BMS-986325.

Timeline

Start

2021-02-16

Primary completion

2023-07-25

Completion

2023-07-25

Outcome

Outcome not reported

Stopped (Enrollment): “Insufficient enrollment”

Drugs

Indications